Rapid resolution of diffuse warts following initiation of dupilumab for severe atopic dermatitis

Pediatr Dermatol. 2024 Mar-Apr;41(2):275-278. doi: 10.1111/pde.15414. Epub 2023 Sep 8.

Abstract

Cutaneous warts are an exceedingly common cutaneous viral infection for which existing treatment options are often painful, expensive, and only marginally effective. Extensive warts may occur in the setting of primary immunodeficiencies, wherein they can co-occur with other diseases of immune dysfunction, such as atopic dermatitis (AD). Dupilumab, an IL-4 receptor α (IL-4Rα)-blocking monoclonal antibody, is a biologic agent recently approved for the treatment of moderate-to-severe eczema. Here, we report a case of a young girl with both severe AD and diffuse filiform warts, which resolved shortly after initiating treatment for AD with dupilumab.

Keywords: atopic dermatitis; cutaneous warts; dupilumab; immunomodulation; primary immunodeficiency.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Dermatitis, Atopic* / drug therapy
  • Female
  • Humans
  • Severity of Illness Index
  • Treatment Outcome
  • Warts* / drug therapy

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized